Last reviewed · How we verify
APD356
APD356 is a selective agonist of the cannabinoid receptor type 2 (CB2).
APD356 is a selective agonist of the cannabinoid receptor type 2 (CB2). Used for Multiple sclerosis.
At a glance
| Generic name | APD356 |
|---|---|
| Sponsor | Eisai Inc. |
| Drug class | CB2 receptor agonist |
| Target | CB2 |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
By activating CB2 receptors, APD356 is thought to modulate the immune response and potentially reduce inflammation. This mechanism may be beneficial in treating various inflammatory conditions.
Approved indications
- Multiple sclerosis
Common side effects
- Nausea
- Headache
- Fatigue
Key clinical trials
- Rebalancing the Serotonergic System in Cocaine Dependence (PHASE1)
- A Study of Lorcaserin as Adjunctive Treatment in Participants With Dravet Syndrome (PHASE3)
- Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
- Lorcaserin in Obesity: Identification of CNS Targets Using FMRI (PHASE4)
- Extended Access Program With Lorcaserin For The Treatment of Dravet Syndrome and Other Refractory Epilepsies
- Predictors of Lorcaserin-Induced Weight Loss (PHASE4)
- Treatment With Lorcaserin for Cocaine Use: The TLC Study (PHASE2)
- Pharmacokinetic Properties of Lorcaserin in Obese or Overweight Elderly Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- APD356 CI brief — competitive landscape report
- APD356 updates RSS · CI watch RSS
- Eisai Inc. portfolio CI